GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2014

BioMarin Nabs Repligen's HDACi Compound Library

  • BioMarin Pharmaceutical is buying Repligen's histone deacetylase inhibitor (HDACi) library, along with the intellectual property related to it. BioMarin is paying Repligen $2 million up front and, per their agreement, will also provide Repligen any potential future milestone and royalty payments for developing, selling, and getting regulatory approval for the compounds.

    BioMarin's CEO Jacques Bienaime said in a statement that the agreement is part of the firm's strategy to acquire preclinical programs that it can develop for people with serious unmet medical needs. The compounds, the firm says, could potentially be applied to Friedreich's ataxia and other neurological disorders.

    "Fredreich's ataxia is a neurological disorder that affects tens of thousands of young people in the developed world, and we look forward to the opportunity to move a compound into the clinic in this indication," Bienaime added.

    Biomarin has been busy lately: In November the FDA voted to approve its investigational drug Vimizim for the treatment of the ultra-rare lysosomal storage disorder Morquio A syndrome. The next day, Myriad Genetics announced a research collaboration with BioMarin to use Myriad's HRD (Homologous Recombination Deficiency) test to identify tumor types that may be sensitive to BioMarin's investigational product candidate, BMN-673.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?